Exploratory Study of the Digital Therapeutics CT-155 in the Treatment of People With Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05438160 |
Recruitment Status :
Completed
First Posted : June 29, 2022
Last Update Posted : August 22, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Device: Digital therapeutics app CT-155 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multi-center, Exploratory, Single-Arm, 7-week Study to Evaluate the Feasibility and Acceptability of the Treatment Monitoring and Educational Components of CT-155 in People With Schizophrenia |
Actual Study Start Date : | March 31, 2022 |
Actual Primary Completion Date : | July 31, 2022 |
Actual Study Completion Date : | July 31, 2022 |
Arm | Intervention/treatment |
---|---|
Schizophrenia treated with digital therapeutics app CT-155
Single group of People with Schizophrenia to be treated with digital therapeutics app CT-155
|
Device: Digital therapeutics app CT-155
Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones |
- To explore feasibility and acceptability of the treatment monitoring and educational components of CT-155 app [ Time Frame: Day 49 at the end of treatment period ]Degree of participant engagement with the study app as measured by participant app use data captured in-app
- Change from Week 3 of the Mobile Agnew Relationships Measure [ Time Frame: Change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure ]
To explore the establishment of a digital working alliance over the course of the Study as assessed by the change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure.
The Mobile Agnew Relationships Measures is on a 7-item scale that ranges from "Strongly Disagree" as scale 1 to "Strongly Agree" as scale 7.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1. Has outpatient treatment status of schizophrenia.
- 2. Is on a stable dose of antipsychotic medication(s)
- 3. Is the sole user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.
- 4. Is the owner of, and has regular access to, an email address.
- 5. Has regular access to the internet via cellular data plan and/or wifi.
- 6. Willing and able to receive SMS text messages on their smartphone and email messages, and understand how to use the downloaded Study App.
- 7. Has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study
Exclusion Criteria:
- 1. Is currently treated with more than two antipsychotic medications.
- 2. Is currently treated with clozapine or haloperidol.
- 3. Has active prominent positive symptoms to preclude effective engagement in treatment for negative symptoms.
- 4. Is currently receiving or has received psychotherapy within 12 weeks prior to screening.
- 5. Meets either the International Classification of Diseases (ICD-10) or DSM-5 criteria for diagnoses not under investigation.
- 6. Has post-traumatic stress disorder (PTSD), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder.
- 7. Has substance or alcohol use disorder.
- 8. Currently needs or will likely require prohibited concomitant medications.
- 9. Is currently participating in another clinical study.
- 10. Prior participation in the CT-155-C-001 clinical study.
- 11. Has suicidal ideation or behavior.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05438160
United States, California | |
CT-155 Center | |
Anaheim, California, United States, 92805 | |
CT-155 Center | |
Torrance, California, United States, 90502 | |
United States, Florida | |
CT-155 Center | |
Hialeah, Florida, United States, 75062 | |
CT-155 Center | |
Lake Mary, Florida, United States, 32746 | |
CT-155 Center | |
Miami, Florida, United States, 33176 | |
United States, Texas | |
CT-155 Center | |
Irving, Texas, United States, 75062 | |
CT-155 Center | |
Richmond, Texas, United States, 77407 |
Study Chair: | Shaheen Lakhan, MDPhD, FAAN | Click Therapeutics |
Responsible Party: | Click Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05438160 |
Other Study ID Numbers: |
CT-155-C-003 |
First Posted: | June 29, 2022 Key Record Dates |
Last Update Posted: | August 22, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Prescription digital therapeutics Smartphone app Schizophrenia |
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders |
Coal Tar Keratolytic Agents Dermatologic Agents |